2 blue chip ASX 200 shares analysts rate as buys this month

These blue chip shares could be buys…

| More on:
A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you’re looking to strengthen your portfolio with some blue chip shares, you may want to look at the two listed below.

Here’s why these blue chip ASX 200 shares are highly rated right now:

CSL Limited (ASX: CSL)

The first blue chip ASX 200 share to look at is CSL. This biotherapeutics giant could be a top option for investors after a very poor start to 2022. Especially given the potential positive catalysts that are on the horizon that could be supportive of a share price recovery.

That’s the view of the team at Citi, which currently has a buy rating and $335.00 price target on the company’s shares.

The broker commented: “Over the next six months, we expect the market to focus on the strong underlying plasma market demand, and the closure the Vifor deal, both of which should lead to strength in the share price.”

Based on the current CSL share price of $264.95, Citi’s price target implies potential upside of 26% for investors over the next 12 months.

ResMed Inc (ASX: RMD)

Another high quality ASX 200 share for investors to consider is ResMed.

It is a global leader in the development, manufacturing, distribution, and marketing of medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders. This includes sleep apnoea and chronic obstructive pulmonary disease (COPD).

Analysts at Morgans believe the company is well-placed for growth over the long term. This is thanks to a recovery in sleep apnoea volumes post-pandemic and its growing digital health business. The broker has an add rating and $40.46 price target on the company’s shares.

Morgans commented: “While we believe the next few quarters will likely be volatile, as Covid-related demand for ventilators continues to slow and core sleep apnoea volumes gradually lift, nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.”

Based on the current ResMed share price of $31.61, Morgans’ price target suggests there’s potential upside of 28% for investors.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

A happy woman in an office puts her hands in the air as if to celebrate while looking at computer.
Blue Chip Shares

Here are 2 blue chip ASX shares analysts rate as buys

Here are two ASX blue chip shares to buy...

Read more »

Woman in mustard yellow blouse on laptop holds both hands out to either side with graphic illustration of question marks above them
Blue Chip Shares

Are these blue chip ASX 200 shares in the buy zone?

Are these blue chips in the buy zone?

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Experts say investors should buy these top blue chip ASX shares

Analysts are saying that these blue chip shares are in the buy zone…

Read more »

shares record high
Blue Chip Shares

Broker names 2 of the best ASX 200 shares to buy now

Here are two high quality ASX 200 shares rated as buys...

Read more »

Three young people in business attire sit around a desk and discuss.
Blue Chip Shares

Why I would invest $10,000 in these 3 ASX shares

Here's why I think these could be some of the best shares to buy...

Read more »

Two businesspeople walk together in an office, smiling as they enjoy a good business relationship.
Blue Chip Shares

Experts rate these ASX 200 blue chip shares as buys

These blue chips have been named as buys...

Read more »

A female stockbroker reviews share price performance in her office with the city shown in the background through her windows
Blue Chip Shares

2 blue chip ASX 200 shares Morgans rates as buys

These two ASX 200 blue chip shares are highly rated...

Read more »

A group of stockbrokers sit in a room with several computer screens in front of them as they discuss the Zip share price and Zip's merger with Sezzle
Blue Chip Shares

2 blue chip ASX 200 shares that Goldman Sachs rates as buys

These ASX 200 shares could be buys according to Goldman Sachs...

Read more »